designed a metal‐organic framework‐based nanoagonist (DZ@A7) with NIR/TME‐responsive decomposition properties, enabling tumor‐specific STING activation for enhanced photodynamic metalloimmunotherapy.[119b] The nanoparticles were fabricated by mixing Zn2+ and 2‐methylimidazole to form ZIF‐8, a framework with a large surface and high porosity. Here, STING1 is linked to neoplasm.